Trail enhancers for the selective killing of cancer cells
The invention is directed to methods of inducing apoptosis, arresting cell cycle, or inhibiting cellular proliferation, or any combination thereof, in a tumor cell, by administration of an effective amount of an N-acyl homoserine lactone analog (AHL), optionally in conjunction with a tumor modulating agent such tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) to the patient. Novel bioactive analogs of an N-acyl homoserine lactone are also provided.
1. A pharmaceutical composition comprising an effective amount of an N-acylhomoserine lactone (AHL) analog compound of formula (I):
wherein R is a linear alkyl, alkenyl or alkynyl of about 9 to about 15 carbon atoms having one or more diazirenyl groups, optionally having one or more carbonyl groups at positions 4 or greater on the alkyl, alkenyl or alkynyl groups, and further optionally substituted with azido, hydroxyl, or halo; or a pharmaceutically acceptable salt thereof; and, optionally,
a pharmaceutically acceptable excipient.
2. The pharmaceutical composition of claim 1 , wherein the compound is of formula (II)
wherein R 1 is a linear alkyl, alkenyl or alkynyl of about 7 to 13 carbon atoms, optionally having one or more of:
a diazirenyl group;
one or more carbonyl groups; or
one or more independently selected azido, hydroxyl, or halo groups.
3. The pharmaceutical composition of claim 1 , further comprising a tumor modulating agent that is a TRAIL polypeptide.
4. The pharmaceutical composition of claim 1 , wherein the N-acylhomoserine lactone (AHL) analog is selected from the group consisting of:
5. A method of treating a tumor in a patient, comprising administering to the patient an effective amount of an N-acylhomoserine lactone (AHL) analog compound of formula (I)
wherein R is a linear alkyl, alkenyl or alkynyl of about 9 to about 15 carbon atoms having one or more diazirenyl groups, optionally having one or more carbonyl groups, and further optionally substituted with azido, hydroxyl, or halo; or a pharmaceutically acceptable salt; and optionally, a pharmaceutically acceptable excipient,
wherein the tumor is selected from the group consisting of lung, cervical, breast, and brain tumors.
6. The method of treating a tumor in a patient of claim 5 , wherein the compound is a compound of formula (II)
wherein R 1 is a linear alkyl, alkenyl or alkynyl of about 7 to 13 carbon atoms, optionally having one or more of:
a diazirenyl group;
one or more carbonyl groups; or
one or more independently selected azido, hydroxyl, or halo groups.
7. The method of treating a tumor in a patient of claim 5 , further comprising administering an effective amount of a tumor modulating agent that is a TRAIL polypeptide.
8. The method of treating a tumor in a patient of claim 5 , wherein the N-acylhomoserine lactone (AHL) analog is selected from the group consisting of:
9. A compound of formula (I):
wherein R is a linear alkyl, alkenyl or alkynyl of about 9 to about 15 carbon atoms having one or more diazirenyl groups, optionally having one or more carbonyl groups at positions 4 or greater on the alkyl, alkenyl or alkynyl groups, and further optionally substituted with azido, hydroxyl, or halo; or, a pharmaceutically acceptable salt thereof.
10. The compound of claim 9 , wherein the compound is a compound of formula (II)
wherein R 1 is a linear alkyl, alkenyl or alkynyl of about 7 to 13 carbon atoms, optionally having one or more of:
a diazirenyl group;
one or more carbonyl groups; or
one or more independently selected azido, hydroxyl, or halo groups.
11. The compound of claim 9 , in a pharmaceutical combination with a tumor modulating agent that is a TRAIL polypeptide.
12. The compound of claim 9 , wherein the N-acylhomoserine lactone (AHL) analog is selected from the group consisting of:
13. A method for inducing apoptosis, arrest of cell division, or inhibition of cell proliferation, in a tumor cell, comprising contacting the cell with an effective amount of an N-acylhomoserine lactone (AHL) compound, and an effective amount of a TRAIL, wherein the AHL compound is of formula (I):
wherein R is a linear alkyl, alkenyl or alkynyl of about 9 to about 15 carbon atoms having one or more diazirenyl groups, optionally having one or more carbonyl groups, and further optionally substituted with azido, hydroxyl, or halo,
wherein the tumor cell is selected from the group consisting of lung tumor cells, cervical tumor cells, breast tumor cells, and brain tumor cells.
14. The method for inducing apoptosis, arrest of cell division, or inhibition of cell proliferation, in a tumor cell, of claim 13 wherein the AHL analog in the effective amount is an activator of the unfolded protein response (UPR), of endoplasmic reticulum swelling (ERS), or both, in the tumor cell.
15. The method for inducing apoptosis, arrest of cell division, or inhibition of cell proliferation, in a tumor cell, of claim 13 wherein the compound is a compound of formula (II)
wherein R 1 is a linear alkyl, alkenyl or alkynyl of about 7 to 13 carbon atoms, optionally having one or more of:
a diazirenyl group;
one or more carbonyl groups; and
one or more independently selected azido, hydroxyl, or halo groups.
16. The method for inducing apoptosis, arrest of cell division, or inhibition of cell proliferation, in a tumor cell, of claim 13 wherein the N-acylhomoserine lactone (AHL) analog is selected from the group consisting of: